Detail Clinical Implementation and Benefits of Pharmacogenomic Testing by Nalagenetics (article of Prosiding Webinar Biomedicine and Biomedical Engineering in Era 4.0 Sabtu, 12 Februari 2022) Bibliografi Author: Lonah Topik: Adverse Drug Reactions (ADRs); Genomic variants; Pharmacogenomics (PGx); JABFUNG-FKIK-LON-2022-04 Bahasa: (ID )     Penerbit: Fakultas Kedokteran Universitas Kristen Maranatha, Universitas Kristen Krida Wacana, dan Unika Widya Mandala Surabaya     Tempat Terbit: Bandung    Tahun Terbit: 2022     Jenis: Papers/Makalah - pada seminar nasional Fulltext: Pharmacogenomic Testing by Nalagenetics.pdf (1.01MB; 2 download) Abstract The established contribution of genetic variation to drug response has the potential to improve drug efficacy and reduce drug toxicity. Patients’ responses to pharmacological treatments are highly variable, ranging from effective treatments to fatal adverse drug reactions (ADRs). Some of this variation is attributable to inherited genetic differences, and many genomic variants influencing responses to frequently used drugs have been identified. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) is the science of identifying and validating genomic variants influencing drug response and implementing strategies to use such genomic information to inform treatment decisions. Recently, health care has been shifting from a “one size fits all” model to a precise personalized regimen. The successful development of a clinical implementation model for PGx may accelerate the pharmaceutical and health care sectors globally by facilitating drug development and improved drug safety and efficacy. Opini Anda Klik untuk menuliskan opini Anda tentang koleksi ini! Lihat Sejarah Pengadaan  Konversi Metadata   Kembali

Copyright © 2006, 2007 Unika Atma Jaya, all rights reserved